Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Refined phenotyping and personalized targeting of muscle-invasive bladder cancer

Funder: Swiss National Science Foundation

Funding period
CHF 692 K
USD 703 K
Funding amount
Abstract
Bladder cancer is a lethal disease and half of patients with MIBC will succumb to their disease despite optimal therapy. Molecular subtypes of MIBC provides a framework for the understanding of the biology of this disease and these subtypes show differences in response to systemic treatments (e.g. to cisplatin or novel targeted therapies). We discovered genomic test, that determines the molecular subtype in a single patient tumor. This allows us to select tumors with a specific molecular subtype for further investigation. In this proposal, we aim to characterize patient derived models for the investigation of tumors of specific molecular subtypes. Furthermore, we will determine whether the investigation of the genomic landscape of bladder cancer specimens allow to predict treatment response. This proposal will serve as proof of concept, that molecular profiles allow to determine the molecular phenotype of the subsequent patient derived models and to predict their responsiveness in a personalized manner.
Similar projects All >
Sorted by: Start Date
Project list item
Investigating underlying molecular mechanisms of epigenetic therapies in muscle-invasive bladder cancer

Bladder Cancer Advocacy Network to Swathi Ramakrishnan

USD 1,700
2019 - 2019
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Targeting FGF in Bladder cancer after Neoadjuvant Immunotherapy and Surgery

American Association For Cancer Research to Joshua James Meeks

USD 25,000
2019 - 2020
Project list item
Identifying Immunological Basis for Bladder Cancer Sex Bias

Canadian Institutes of Health Research to Hyunwoo Kwon, Zihai Li

USD 26,219
2019 - 2022

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Biotechnology

  • RCDC

    Human Genome

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Genetics

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science